Tp47. Tp047 Covid and Ards Case Reports 2021
DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2443
|View full text |Cite
|
Sign up to set email alerts
|

"Toci Associated Toxicity" - A Report of Tocilizumab Associated Bowel Perforation in Two Critically Ill Patients with COVID-19 Pneumonia

Abstract: INTRODUCTION:The advent of corona virus disease as a global health emergency has resulted in the trial of several empiric pharmacological regimens, many of which are associated with deleterious adverse effects. However, because of the lack of viable treatments and rapidity of spread, physicians around the world have used them in an attempt to improve survival in critically ill patients. One such drug is Tocilizumab, which was hypothesized to have a role in managing the cytokine release syndrome ("Cytokine sto… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“… 4 With concerns to abdominal perforation in COVID-19 patients, tocilizumab, an approved treatment by the CDC, has been linked to such adverse effects. Asharaf and Papierniak 6 note a higher incidence for GI perforation in patients with previous corticosteroid use or preexisting diverticulitis. In addition, they state that increased expression of IL-6 stimulates epithelial proliferation, which was significantly reduced in patients at higher risk of intestinal perforation.…”
Section: Discussionmentioning
confidence: 98%
See 2 more Smart Citations
“… 4 With concerns to abdominal perforation in COVID-19 patients, tocilizumab, an approved treatment by the CDC, has been linked to such adverse effects. Asharaf and Papierniak 6 note a higher incidence for GI perforation in patients with previous corticosteroid use or preexisting diverticulitis. In addition, they state that increased expression of IL-6 stimulates epithelial proliferation, which was significantly reduced in patients at higher risk of intestinal perforation.…”
Section: Discussionmentioning
confidence: 98%
“…In addition, they state that increased expression of IL-6 stimulates epithelial proliferation, which was significantly reduced in patients at higher risk of intestinal perforation. 6 It is also important to mention that no adverse GI effects have been reported using convalescent plasma. 7 Tocilizumab, an IL-6 receptor antagonist, was initially approved by the Food and Drug Administration (FDA) for adults with moderate to severe rheumatoid arthritis and children ages 2 and old with either active Polyarticular Juvenile Idiopathic Arthritis or active Systemic Juvenile Idiopathic Arthritis.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation